Peter Rose, MD
Gynecologic Oncology · Cleveland, OHNPI 1972530293
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,445 of the $3,755 with a category attached, or 65.1%. Eisai Inc. accounts for 67.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $2,620 and has fallen 95.4% since, to $121 in 2025.
Across 21 payments — averaging $178.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$3K
- GSK$475
- Tesaro, Inc.$284
- AstraZeneca$201
- Clovis Oncology, Inc.$125
- Seagen Inc.$43
- plus $82 from 3 others
Across 254 payments — averaging $5213.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$263K
- Tesaro, Inc.$259K
- Seagen Inc.$205K
- Genentech, Inc.$130K
- AbbVie$112K
- Merck$104K
- plus $251K from 9 others
What the payments were for
- Consulting fees$2,44565%
- Food & beverage$1,31035%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 3 | $2,545 |
| GSK | 7 | $475 |
| Tesaro, Inc. | 4 | $284 |
| AstraZeneca | 2 | $201 |
| Clovis Oncology, Inc. | 1 | $125 |
| Seagen Inc. | 1 | $43 |
| Merck | 1 | $43 |
| Medtronic | 1 | $28 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,755 in reported general payments places this provider in the 70th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 34 | $616,742 |
| LenvimaLenvatinib Mesylate | 17 | $408,112 |
| Letrozole | 15 | $216 |
| Anastrozole | 14 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $475 | $616,74234 claims |
| Eisai Inc.Lenvima | $2,545 | $408,11217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 62 gynecologic oncology providers in Ohio.
Other gynecologic oncology in Cleveland
- Amelia JerniganCleveland$85K
- Kimberly ResnickCleveland$29K
- Kevin EliasCleveland$4K
- Chad MichenerCleveland$3K
- Mariam Al HilliCleveland$2K
- Robert DebernardoCleveland$2K
- Anthony RizzoCleveland$1K
- Lisa Rauh-BenoitCleveland$930
- Roberto VargasCleveland$482
- Lindsay FergusonCleveland$467
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.